What is the 13F Pro Quality Score for CRVS?

13F Pro ranks Corvus Pharmaceuticals, Inc. (CRVS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRVS's current score at https://13fpro.ai/research/CRVS (free sign-up required for the full ranking).

Which hedge funds own the most CRVS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRVS include ORBIMED ADVISORS, BlackRock,, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CRVS as soon as new 13F filings post.

Where does 13F Pro source CRVS data?

All Corvus Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Corvus Pharmaceuticals, Inc. files with the SEC under CIK 1626971. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRVS in?

Corvus Pharmaceuticals, Inc. (CRVS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRVS research updated on 13F Pro?

CRVS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Corvus Pharmaceuticals, Inc.(CRVS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1626971 CRVS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CRVS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Corvus Pharmaceuticals, Inc. (CRVS), a Healthcare sector company. CRVS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Corvus Pharmaceuticals, Inc. reports net income of $-13.7M, free cash flow of $-10.5M. Top institutional holders of CRVS by reported 13-F value include ORBIMED ADVISORS, BlackRock,, STATE STREET, based on the most recent SEC filings. CRVS trades on the Nasdaq exchange and files with the SEC under CIK 1626971. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Corvus Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-13.7M

Free Cash Flow

Q1 2026

$-10.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-621.3% YoY

$-43.2MFY 2021

FY18 $-46.9MFY19 $-46.7MFY20 $-6.0MFY21 $-43.2M

Operating Income

+11.7% YoY

$-38.6MFY 2021

FY18 $-49.2MFY19 $-48.9MFY20 $-43.8MFY21 $-38.6M

EPS (Diluted)

-415.0% YoY

$-1.03FY 2021

FY18 —FY19 $-1.59FY20 $-0.20FY21 $-1.03

Total Assets

+28.0% YoY

$109.5MFY 2021

FY18 $118.2MFY19 $83.6MFY20 $85.5MFY21 $109.5M

Op. Cash Flow

-5.6% YoY

$-36.7MFY 2021

FY18 $-41.0MFY19 $-37.3MFY20 $-34.8MFY21 $-36.7M

Metric	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Net Income	$-43.2M -621.3%	$-6.0M +87.2%	$-46.7M +0.6%	$-46.9M +15.7%	$-55.7M -53.0%	$-36.4M
Operating Income	$-38.6M +11.7%	$-43.8M +10.4%	$-48.9M +0.7%	$-49.2M +12.9%	$-56.5M -52.9%	$-37.0M
EPS (Diluted)	$-1.03 -415.0%	$-0.20 +87.4%	$-1.59	—	—	—
Total Assets	$109.5M +28.0%	$85.5M +2.3%	$83.6M -29.3%	$118.2M +24.8%	$94.8M -32.4%	$140.2M
Operating Cash Flow	$-36.7M -5.6%	$-34.8M +6.8%	$-37.3M +8.9%	$-41.0M +11.3%	$-46.2M -65.9%	$-27.9M

AI Insight: CRVS Financial Trends

A massive equity raise in Q1 2026 lifted stockholders' equity to $241M, but operating cash burn is accelerating with no revenue in sight.

• Operating losses have widened steadily from -$6M in Q2 2024 to -$15M in Q1 2026, reflecting escalating R&D spend.

• Operating cash outflows deepened from -$5M in Q2 2024 to -$10M in Q1 2026, with no revenue to offset burn.

• Equity surged from $61M in Q4 2025 to $241M in Q1 2026, suggesting a significant capital raise that extends the runway.

⚠ Monthly cash burn is accelerating; at -$10M operating CF in Q1 2026, the $241M equity cushion could deplete faster than expected.

⚠ Revenue remains absent across all eight quarters — any catalyst triggering first commercial or licensing revenue is the key inflection.

⚠ The Q1 2025 net income spike to $15M amid -$10M operating income warrants scrutiny — likely a one-time non-operating gain, not operational progress.

AI Insight: CRVS Ratio Trends

CRVS remains deeply loss-making, though TTM ROIC of -19.9% marks a meaningful improvement from the -99.6% trough in Q4 2024.

• ROIC deteriorated sharply to -99.6% in Q4 2024 before recovering to -24.7% in Q1 2026, suggesting reduced capital burn intensity.

• ROE swung from -148.8% in Q4 2024 to an anomalous +123.2% in Q1 2025, then resumed negative territory through Q1 2026 at -22.8%.

• ROA has remained consistently negative across all reported quarters, ranging from -17.4% (TTM) to -70.3% (Q4 2024), confirming persistent net losses.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods — critical profitability and leverage data unavailable for full assessment.

⚠ ROIC worsened sequentially from -51.1% in Q2 2025 to -79.8% in Q4 2025 before improving — trend sustainability in Q1 2026 is unconfirmed.

Get alerted when CRVS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Corvus Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRVS

ORBIMED ADVISORS LLC
$104.8M7,165,006 sh
BlackRock, Inc.
$90.1M6,160,422 sh
STATE STREET CORP
$52.2M3,565,992 sh
ADAMS STREET PARTNERS LLC
$47.9M3,275,616 sh
VANGUARD CAPITAL MANAGEMENT LLC
$47.3M3,234,538 sh
Vivo Capital, LLC
$41.0M2,805,816 sh
MORGAN STANLEY
$36.6M2,498,825 sh
Deep Track Capital, LP
$36.5M2,491,539 sh
WELLINGTON MANAGEMENT GROUP LLP
$33.9M2,318,517 sh
PERCEPTIVE ADVISORS LLC
$33.5M2,292,441 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$104.8M	7,165,006
BlackRock, Inc.	$90.1M	6,160,422
STATE STREET CORP	$52.2M	3,565,992
ADAMS STREET PARTNERS LLC	$47.9M	3,275,616
VANGUARD CAPITAL MANAGEMENT LLC	$47.3M	3,234,538
Vivo Capital, LLC	$41.0M	2,805,816
MORGAN STANLEY	$36.6M	2,498,825
Deep Track Capital, LP	$36.5M	2,491,539
WELLINGTON MANAGEMENT GROUP LLP	$33.9M	2,318,517
PERCEPTIVE ADVISORS LLC	$33.5M	2,292,441

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRVS on your watchlist

Track score changes the day Corvus Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRVS a good stock to buy?

13F Pro's AI-powered analysis of Corvus Pharmaceuticals, Inc. (CRVS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRVS are available on the CRVS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CRVS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRVS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Corvus Pharmaceuticals, Inc.'s investment landscape.